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Abstract
Background: Neuroblastoma (NB) is the principal tumor of the sympathetic nervous system in
children under one year of age. The incidence in developed countries is greater than that in
developing countries. The aim of this article is to present the epidemiological and some clinical
characteristics of Mexican children with NB.
Methods: A population-based, prolective study, with data obtained from the Childhood Cancer
Registry of the Instituto Mexicano de Seguro Social. Statistical analysis: The simple frequencies of
the variables of the study and the annual average incidence (per 1,000,000 children/years) by age
and sex were obtained. The trend was evaluated by calculating the annual percentage of change.
The curves of Kaplan-Meyer were employed for the survival rate and the log-rank test was used to
compare the curves.
Results: Of a total of 2,758 children with cancer registered during the period from 1996–2005, 72
(2.6%) were identified as having Group IV, defined according to the International Classification of
Childhood Cancer. The incidence for NB was 3.8 per 1,000,000 children/year; NB was highest in
the group of children under one year of age, followed by the group of children between the ages
1–4 years (18.5 and 5.4 per 1,000,000 children/years, respectively). The male/female ratio was 1.1
and there was no trend toward an increase. The time of diagnosis was 26 days (median), but varied
according to the stage at diagnosis. Stages III and IV were presented in 88% of the cases. There was
no association between the stage, the age at time of diagnosis, or the histological pattern. The
overall five-year survival rate was 64%; the patients with stage I, II, III, or IVs did not die; and the
five-year survival rate of cases in Stage IV was 40%.
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BMC Cancer 2009, 9:266 http://www.biomedcentral.com/1471-2407/9/266Conclusion: It is possible that the low incidence of neuroblastoma in Mexican children is due to
the difficulty in diagnosing the cases with the best prognosis, some of which could have had
spontaneous regression. There was no trend to an increase; the majority of the cases were
diagnosed in the advanced stages; and the overall five-years survival rate was similar to that for
developed countries.
Background
During fetal life, cells of the neural crest colonize the sym-
pathetic ganglions, the medulla of adrenal glands, and
other sites. Neuroblastoma (NB) and related tumors [gan-
glioneuroblastoma (GNB) and anaplastic ganglioglioma]
arise from these cells. These neoplasias are in the family of
tumors characterized by diverse biological and clinical
behaviors that range from spontaneous regression or dif-
ferentiation into benign neoplasias, principally in chil-
dren under one year of age, to very aggressive metastasis
in older children [1,2]
According to the International Classification of Child-
hood Cancer (ICCC) [3], NB and other tumors of the
peripheral nerve cells (NB-O) are classified in Group IV.
Together, NB and GNB comprise 97% of the tumors in
this group [4]. The adrenal gland is the topographical site
where NB is most frequently found [1].
NB represents between 8–10% of the total cancers in chil-
dren (0–14 years) in countries such as the United Stated
of America (USA), Australia, and those in Europe, whereas
the frequency is generally lower (3%) in Latin-American
countries and in some cities in Asia, such as Tianjin,
China, and Delhi and Madras, India [5]. In developed
countries, the annual average incidence of NB in children
varies between 7 and 14 per 1,000,000 children/years; in
some of these countries, NB occupies fourth place in inci-
dence. In developing countries, however, the incidence is
low, generally having been reported to be less than 6 per
1,000,000 children/year [5].
We have reported that, in Mexico, the frequency and inci-
dence of NB (2.7% and 3.6 per 1,000,000/year, respec-
tively) are similar to the values found for developing
countries [6]; however, in that study, we reported neither
the trends, nor the incidence according to age, sex, or clin-
ical characteristics, such as the time of diagnosis (TD), the
stage, and the five-year survival rate of the patients. For
this reason, the objective of this article is to present the






New cases of NB and NB-O in children under 15 years of
age, who fulfilled the following criteria: they had the right
to service from IMSS; were attended either in the Pediatric
Hospital (PH) of the Siglo XXI National Medical Center of
IMSS or in the Pediatric Oncological Service of the Gen-
eral Hospital La Raza Medical Center, IMSS; and were res-
idents either in Mexico City or in the following four states
of the Republic of Mexico: Mexico State, Morelos, Guer-
rero, or Chiapas.
Study period
From January 1, 1996 to December 31, 2005.
Process for collection of data
The data were obtained from the Registry of Childhood
Cancer of the Instituto Mexicano de Seguro Social (RCN-
IMSS) that is maintained in the Research Unit of Clinical
Epidemiology of the PH. This Registry was started in 1996
and is ongoing. IMSS is the principal institution that pro-
vides medical attention in Mexico, serving 41% of the
population of the country. The method of collection and
the coding and registry of data in the RCN-IMSS have
been described in detail [6]. Therefore, in this paper, we
will summarize those aspects that are most relevant for
the registry of cases of NB and NB-O.
All the cases of NB and NB-O, which were registered dur-
ing the period of study, were analyzed. The cases were
coded following their morphology and topography, in
accord with the third edition of the International Classifi-
cation of Disease for Oncology [7]; in all cases, the diag-
nosis was confirmed by histopathological studies. The site
of origin of the tumor in the child's body (topography)
was determined from the clinical data taken when the
patient presented, from the imaging studies (radio-
graphic, ultrasound, and/or tomography), and from the
surgical findings when the child underwent surgery. Also,
to evaluate the metastasis of the tumor at the TD when
surgery was used either as a method of diagnosis and/or
treatment, the criteria of the International Neuroblastoma
Staging System [8] were used. In those cases in which sur-
gery was not performed, the criteria of the Children's Can-
cer Group Neuroblastoma Staging system [9] were used.
Also, the prognostic evaluation of the patients with NB
(favorable or unfavorable histology) was carried out byPage 2 of 8
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Pathology Classification System [10]. This last technique
was used in only 22 cases, because this diagnostic tool was
performed in only one hospital (PH) included in the
RCN-IMSS.
The family history of cancer was obtained through the
analysis of the genealogical trees of each patient with NB
for the 1st, 2nd, and 3rd generation (siblings, parents, aunts,
uncles and grandparents). The survivor rate for NB was
determined though a five-year follow-up of the patients
(localization of the patients was done by direct contact at
the hospital or at home, from medical records, institu-
tional archives, telephone, and/or mail).
The TD (also known as lag time) is defined as the period
between the start of the symptoms and the date of the his-
topathological diagnosis of NB; the lag time was regis-
tered in days [11].
To evaluate the internal consistency in the collection of
data and the capture of same, the program Child Check
was used to detect and correct any inconsistencies [12].
Denominators
The reference populations (denominators) were obtained
from the structure of the population assigned to a family
physician of the IMSS [13].
Analysis
The simple frequencies of the different types of cancer, fol-
lowing Group IV of the ICCC, and the topography, stage,
grade, histological differentiation of Shimada [10], and
family history were obtained. Also, the annual average
incidence per period (AAIP; per 1,000,000 children/year)
was estimated. The AAIP was standardized by age through
the direct method, with the value for the world popula-
tion taken as reference population [14]. AAIP was strati-
fied by age and sex. The trends of the incidence during the
study period was evaluated by calculating the average
annual percent change (AAPC) and the confidence inter-
val at 95% (CI95%) [15]. For the TD, the median, and
interquartile ranges (25–75th percentile) were obtained.
The association between the stage and the median TD was
analyzed by using Kuskal-Wallis statistics. The Kaplan-
Meyer method was used for survival rate analysis and the
Log-rank test was used to compare the curves [16]
Results
During the period under study, there was a total of 2,758
new cases of childhood cancer, of which 72 (2.6%) were
determined to be Group IV of the ICCC. The frequency of
the subgroup of NB was 94.4% (Table 1).
The incidence of NB for the period under study was 3.8
cases per 1,000,000 of children/year and the male/female
ratio was 1.1 (Table 2). According to age, the highest inci-
dence was found in children under one year of age and the
second highest was in the 1–4 year-old age group, the
rates being 18.5 and 5.4 cases per 1,000,000 children/
year, respectively. In the groups 5–9 year-olds and 10–14
year-olds, the incidence was very low. Median age at diag-
nosis was 27 months [interquartile range (25–75th) 8.5
and 48 months]. During the period under study, the
trends of NB remained stable (AAPC = 2.3; CI95%, -8.7,
+14.5) (Table 3).
As for topography, 63.9% of the tumors were in the
abdominal area (34.5% in the adrenal gland), 12.1% in
the face or neck, and 10.3% in the thorax and 10.3% in
the pelvis; the site of origin could not be determined in
only 3.4% of the cases. Of the 68 cases with NB, 50 were
staged. Of these 50, 88.0% were classified as Stage III, IV,
or IVs. For children <1 year old, only two cases (11.1%)
were localized stages (I and II) and 12 (66.7%) were dis-
seminated stages (III and IV), with only four cases
(22.2%) being Stage IVs (Table 4).
The median TD was 26 days. The TD differed according to
the stage (P = 0.01): the longest was found for Stage IV
and the shortest for Stage I (median 35.5 and 3 days,
respectively) (Table 5).
Table 1: Frequency and incidence* of neuroblastoma and other peripheral nervous cell tumors in Mexican children (1996–2005)
Diagnostic group n % ASR**
IVa. Neuroblastoma and Ganglioneuroblastoma 68 94.4 3.80
- Neuroblastoma 58 80.5 3.30
- Ganglioneuroblastoma 10 13.9 0.50
IVb. Other peripheral nervous cell tumors 4 5.6 0.16
- Medulloepithelioma 1 1.4 0.04
- Neuroepithelioma 1 1.4 0.04
- Olfatory Neuroblastoma 2 2.8 0.08
TOTAL 72 100.0 3.96
*Rate per 1,000,000 children/year; **ASR: Age-standardized ratesPage 3 of 8
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of cancer. For the 22 cases in which the grade and histo-
logical differentiation of Shimada (favorable or unfavora-
ble histology) were determined, no relation with the stage
of diagnosis was found (Table 6).
The overall five-year survival rate was 64%. Only in those
cases in Stage IV and those for which we could not deter-
mine the stage did the patient die, with the five-year sur-
vival rate for these cases being 85% and 40%, respectively
(Figure 1).
Discussion
In this study, we corroborated the finding that the inci-
dence of NB in Mexican children is low in comparison to
that reported for developed countries. In a previous study
carried out in a population residing in Mexico City and
having right to service from IMSS, an incidence of 3.2
cases per 1,000,000 children/year was found [17], a value
that was thought to be an underestimation because the
study was retrospective. However, this idea can be dis-
carded because the incidence mentioned is very similar to
the value (3.8 cases per 1,000,000 children/year) pre-
sented in the current, more robust study. In contrast to the
prior study, the methodology used in the present study
was of a much better quality: 1) the study was prolective;
2) the personnel that collected, coded, and captured the
data had received better training in registering the cases of
cancer; and 3) the diagnosis was confirmed be means of
an histopathological testing in 100% of the cases.
The incidence reported here is similar to that for Latin
American countries and to that for some Asian and Afri-
can countries [5,18-20]. That is to say, it is probable that
in underdeveloped countries the incidence of NB is truly
much less than that reported for developed countries and
that the difference is not due to incomplete registry of
cases.
For this result, it is of interest to establish the cause(s) of
this low incidence in the population of Mexican children
studied. We hypothesize that some cases of NB in children
under five years of age (an age group in which the inci-
dence is higher) are not diagnosed and such cases undergo
spontaneous regression without the presence of NB ever
having been suspected in the patient, thus resulting in an
lower incidence than that in developed countries.
In relation to the foregoing, it has been pointed out that
NB can exist in three groups of patients: 1) a group, gen-
erally under one or two years of age, in which the tumor
either disappears or matures into a benign tumor (gangli-
oneuroma) spontaneously or with minimum treatment;
2) a group, in which the tumor is curable with current
therapeutics; and 3) a group in which NB is incurable with
current therapy [21].
Mexico lacks the screening programs, such as those used
in several developed countries, by which it has been
shown that patients may have spontaneously regression
in over 50% of the cases [22,23]. Due to the finding that,
in those children less than one year of age, we obtained a
much lower frequency in patients with NB in localized
studies (11.1%) in comparison to that reported in devel-
oped countries (40.5 to 36.0%) [24-26], to the fact that,
generally, the age at diagnosis was greater than two years
old (median of 27 months), and to the fact that, in devel-
oped countries, these cases are diagnosed at a younger age
(median 14.5 to 21.6 months) [27], we think that for
Mexican children, and above all for those under five years
of age, the phenomenon of spontaneous regression is pre-
sented. That is, the children develop the tumor and
Table 2: Incidence* of neuroblastoma in Mexican children by age 
and sex (1996–2005)
Sex
Overall Male Female M/F
Age Group
(years)
n rate n rate n rate Ratio
< 1 26 18.5 16 26.9 10 17.6 1.6
1 – 4 32 5.4 14 4.6 18 6.1 0.8
5 – 9 8 1.1 3 0.8 5 1.3 0.6
10 – 14 2 0.2 2 0.6 0 0.0 -
AAIP 68 2.9 35 3.1 33 3.1 1.0
ASR 68 3.8 35 3.9 33 3.7 1.1
*Rates per 1,000,000 children/year; n, number of cases; M, Male; F, 
Female; AAIP, Average Annual Incidence per Period; ASR, Average 
Standardized Rate.
Table 3: Trend* of neuroblastoma in Mexican children (1996–2005)
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
n = 9 n = 3 n = 6 n = 7 n = 4 n = 6 n = 12 n = 8 n = 8 n = 5 AAPC CI95%
ASR 5.6 1.8 3.3 3.9 2.0 3.0 6.8 4.7 4.3 2.8 2.3 -8.7,+14.5
*Rates per 1,000,000 children/year; n, number of cases; AAPC, Average Annual Percentage Change; CI95%, Confidence Interval; ASR, Average 
Standardized Rate (0 – 14 years).Page 4 of 8
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not request a diagnostic study (such as an ultrasound in
the case of abdominal symptoms) because seldom, within
the limitations of the first level of treatment, do physi-
cians suspect the presence of a neoplasm in a child [28].
Thus, the condition of the patient is left to evolve. If, in
some cases, the tumor spontaneously regressed with the
subsequent disappearance of symptoms, this would
explain the lower incidence that we have encountered. We
intend to corroborate this hypothesis in future studies.
This hypothesis should be corroborated in future studies.
The above-mentioned scenario was reported by Powell et
al. [27] in the late 1990's. These researchers found that the
incidence of NB in the UK was lower (10.1 per 1,000,000
children/year) than that of other European countries
(France, Germany, Austria, with 12.5, 11.4, 11.7 per
1,000,000 children/year, respectively). The age at diagno-
sis was greater than two years (median of 24.8 months),
the frequency of the cases with localized tumors in those
less than one year of age was lower in comparison to these
countries and that of the cases with disseminated tumor
(Stage IV) was greater in children over five years of age.
The authors commented that their findings could be due
to the different health-care systems in the various coun-
tries, but above all to less use of the technology (ultra-
sound) for the diagnosis of NB in the children of the UK.
However, they did not mention whether the lower inci-
dence could have been due to lack of diagnosis and the
spontaneous regression in some cases of non-detected
NB, such as we suspect happens in the population of Mex-
ican children.
On the other hand, the incidence reported for Hispanic
children residing in the United States is low in compari-
son to that for Caucasian children (8.5 vs. 11.5 cases per
1,000,000 children/year), but much higher then the value
that we reported here (3.8 cases per 1,000,000 children/
year) [29,30]. Therefore, we think that, in face of the lack
of environmental factors known to be involved in the
development of NB, it is highly probable that the higher
incidence for Hispanic children in the U.S.A., in compari-
son to that of Mexican children, is due principally to an
increased suspicion of the diagnosis and to the more fre-
quent use of ultrasound technology for its diagnosis.
Also, we think that this possibility, the spontaneous
regression of some NB, was what contributed to the
results for the population in our study generally and, spe-
cifically, to that for the children under one year of age; the
Stages III, IV, and IVs were the most frequent in 88.9% of
Table 4: Stage at diagnosis in Mexican children with neuroblastoma by age groups (1995–2006)
Age groups (years) Stage at diagnosis
I II III IV IVs Total
n % n % n % n % n % n %
< 1 2 11.1 0 0.0 5 27.8 7 38.9 4 22.2 18 100.0
1 – 4 1 4.0 2 8.0 3 12.0 19 76.0 0 0.0 25 100.0
5 – 9 0 0.0 0 0.0 2 33.3 4 66.7 0 0.0 6 100.0
10–14 0 0.0 1 100.0 0 0.0 0 0.0 0 0.0 1 100.0
Total 3 6.0 3 6.0 10 20.0 30 60.0 4 8.0 50 100.0
n: Number of cases
Table 5: Stage at diagnosis by time of diagnosis (lag time) in 
Mexican children with neuroblastoma (1996–2005)
Stage at diagnosis n Time of diagnosis*
Md (25–75%)
I 3 3 (1 – 17)
II 3 26 (12 – 134)
III 10 11 (5 – 40)
IV 30 35.5 (15 – 47)
IVs 4 4 (1.5 – 6.5)
Total 50 26 (8 – 42)**
*Kruskal-Wallis = 12.6; df = 4; P = 0.01; n, number of cases; Md, 
Overall median and interquartile range (25–75th percentile) in days.




Stage at diagnosis n n N
I 0 1 1
II 0 0 0
III 0 2 2
IV 6 11 17
IVs 2 0 2
Total 8 14 22
*Fisher exact test (two tail) = 1.0 (Stage at diagnosis vs histology, two 
by two table)Page 5 of 8
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[2] who found, in children less than five years of age, an
incidence higher than that which we reported. They men-
tioned that, because they did not know the stage of the
cases that they analyzed, they did not find a higher fre-
quency of localized cases in the youngest group. We also
did not find such a situation; however, in our case, this
was due to such cases not having been diagnosed. Thus,
before considering the possibility that Mexican children
may have a lower susceptibility and/or a lower exposure
to risk factors for the development of NB, we must elimi-
nate the possibility that this apparent lower susceptibility
may only be due to reduced suspicion of NB and to the
difficulty in establishing diagnosis of NB in such cases.
Although there was a trend to an increase similar to that
reported by Six et al. for Eastern Europe (AAPC 2.8, P <
0.001) [2] and by Dalmasso et al. for the northwest of Italy
(AAPC 2.3, CI95% 1.0–2.5) [31], the trend that we found
in the Mexican children was not statistically significant
(AAPC 2.3, CI95% -8.7, +14.5). This result is possibly due
to the short period (ten years) covered for our cases in the
Registry. It will be necessary to evaluate the trend, in a
more complete manner, over a longer period of registry.
In general, it has been found that the stages most fre-
quently encountered at diagnosis are Stages III and IV
(both of which are considered to be advanced stages) [32]
or that 70% of the cases of children with NB present with
metastasis at diagnosis [33,34]. Similarly, in another
study carried out in Mexico, Stages III and IV were found
in 80% of the cases [35]. The data in the present study
were consistent with these results, in that the stages most
frequently found were III and IV, with a frequency of 88%
(Table 4). Due to this agreement between our data and
those of various studies, we think that the registered cases
included in the present study were cases without sponta-
neous remission.
With regard to the TD, our data (median of 26 days) for
the population with NB were consistent with those
reported in different studies that have found a median
between 15 and 45 days [36-38]. However, the most
important point is that the TD differed according to the
stage of diagnosis, with Stage IV having the longest TD
(median, 35.5 days). Nevertheless, we think that the asso-
ciation found between TD and the stage, although statisti-
cally significant, could be spurious because Stages I and II
had only three cases each and because the longest TD was
found in Stage II (the value of the 3rd quartile was 134
days). Thus, we think that this association is not conclu-
sive and that it will be necessary to increase the size of the
sample for Stages I and II in order to have better support-
ing evidence.
With regard to the diagnostic stage and the histological
differentiation of Shimada, the latter could only be per-
formed in 32% of the cases (n = 22) and, similar to the lit-
erature, we did not find an association between a
favorable histology and the localized stages (I and II), or
between an unfavorable histological report and advanced
stages (III and IV) [10]. Nevertheless, it will be necessary
to perform a histological evaluation in all the cases that
we study in the future in order to evaluate this correlation
more precisely.
The survival rate found in our population of children with
NB (overall five-year survival rate, 64%) was similar to
that reported in the literature [2,15,33], and was a little
higher than that reported in a prior study performed in
Mexico (overall five-year survival, 53%) [35]. No patient
with Stage I, II, III, or IVs died; for the children with Stage
IV, the survival was 40%. These results indicated that the
treatment offered to the patients with NB in our facilities
was adequate. But only in 79.3% of the total number of
cases did we have a complete follow-up of the patients. It
is known that, when there are losses during the follow-up,
the survival rate may be overestimated [39]. Because this
is a possibility in our case, it will be very important to
implement that will improve the follow-up of these
patients.
Regarding genetic aspects, our results were consistent with
those reported in the literature. It has been pointed out
that NB occurs sporadically and that only for 2% or less of
the patients is there a family medical history of NB; how-
ever, there is a great number of cases of distinct cancers in
the family members of patients with NB [40]. In the
Cumulative survival probabilitiy by stage for Mexican children with neuroblastoma (1996–2005)Figur  1
Cumulative survival probabilitiy by stage for Mexican 
children with neuroblastoma (1996–2005).Page 6 of 8
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tories of NB, but 27.6% of the cases did have a family his-
tory of other cancers. From these data, we think that there
may exist a non-specific genetic susceptibility for NB.
Conclusion
We conclude that the incidence of NB in Mexican children
was low in comparison to that for children in developed
countries, which possibly may be due to some cases, prin-
cipally those of children under the age of five years, pre-
senting spontaneous regression. There was no trend to an
increase in the disease; 80% of the cases were diagnosed
in advanced stages (III and IV), and the mean TD was 26
days. It will necessary to have an improved follow-up for
patients with NB in order to bring about a better evalua-
tion of the global survival.
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